GSK3845097

GSK3845097 is an autologous, genetically engineered **T-cell receptor engineered T-cell therapy** developed by Adaptimmune and formerly partnered with GSK. Patient T cells are modified to express an affinity-enhanced T-cell receptor recognizing the cancer-testis antigens NY-ESO-1 and LAGE-1a in the context of HLA-A*02, together with a dominant-negative transforming growth factor-beta receptor II designed to reduce suppressive transforming growth factor-beta signaling in the tumor microenvironment. The program was evaluated after lymphodepleting chemotherapy in HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06-positive patients with antigen-positive advanced synovial sarcoma or myxoid/round cell liposarcoma. The Phase 1 study NCT05943990 was terminated. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-ny-eso-1-tcr-dntgf-brii-expressing-t-cells-gsk3845097))

Other names

autologous anti-NY-ESO-1 TCR/dominant-negative TGF-beta receptor II-expressing T cells GSK3845097TGF NYESO Product